当前位置:首页 > 报告详情

征服MDR迷宫:专家洞察和真实世界的例子.pdf

上传人: 表表 编号:599472 2025-01-24 24页 6.58MB

1、Sponsored byEhab Esmail,OrthofixMatthias Fink,M.D.,AKRA Team Sandeep Ramineni,Ph.D.,TV SD(slides not available)Conquer the MDR Maze:Expert Insights&Real-World ExamplesConquer the MDR Maze:Expert Insights&Real-World ExamplesEhab EsmailSenior Vice PresidentGlobal Quality,Regulatory and Clinical Affair

2、sPresidentBoard MemberAGENDAMDR Requirements Remediation?Equivalence Medical DevicesSignificant Change vs.Substantial ChangeFDA vs.CE MarkPerson Responsible for Regulatory Compliance(PRRC)1.Gap Analysis and Project PlanningProject Management2.Enhanced Clinical EvidenceClinical ResearchPost-Market Su

3、rveillance3.Technical Documentation UpdateProduct Development Quality Assurance4.UDI Implementation and EUDAMED RegistrationOperations and Manufacturing IT Systems 5.Reclassification of DevicesProduct Development 6.Quality Management System(QMS)UpdateQuality Assurance 7.Supply Chain and Economic Ope

4、rators ComplianceOperations and ManufacturingSales and Marketing&Transportation and Logistics8.Risk Management and Post-Market Activities EnhancementProduct Development&Risk Management:Post-Market Surveillance9.Training and AwarenessAll Functions10.Notified Body Interaction-LeadershipQuality Assuran

5、ceMDR RequirementsRemediations?EquivalenceMedical DevicesEU-MDR Equivalence Pathway-Clinical,Biological and Technical-Access to Competitor DocumentationFDA 510(k)Pathway-Substantial equivalence less stringent-Premarket Approval(PMA)-De NovoSignificant Changevs.Substantial ChangeChart A Intended purp

6、ose changesChart B Design changesChart C Software changesChart D Material or substance/ingredient changesChart E Sterilization changesFDA vs.CE MarkRequirements?Cost?Time?In summaryWhat is the true impact on industry?Legacy devices(Design Controls?)Clinical(Data Collection?)Product obsolescence(Time

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要探讨了欧盟医疗器械法规(EU-MDR)对医疗器械行业的影响,以及与美国食品药品监督管理局(FDA)的监管要求进行了比较。文章指出,EU-MDR要求在临床证据、技术文档、UDI实施和EUDAMED注册等方面进行了增强,并对医疗器械的质量管理体系、供应链经济运营商合规性、风险管理和后市场活动提出了更高要求。同时,文章也提到了医疗器械的分类差异,大约97%的骨科医疗器械通过美国的510(k)程序上市,而在欧盟,这些设备可能面临更高的审查要求。在讨论挑战时,文章强调了 notified bodies 和制造商之间的学习曲线,以及 legacy devices 临床数据的不充分性。最后,文章提到了使用真实世界数据时需要考虑的多种因素,如解剖、人口统计、工作习惯等,以及欧盟成员国之间的健康保健系统差异。
如何应对挑战?" 欧盟与美国有何不同?" 如何在不同 indication 间转移?"
客服
商务合作
小程序
服务号
折叠